<DOC>
	<DOCNO>NCT00003648</DOCNO>
	<brief_summary>RATIONALE : Determination genetic marker colorectal cancer may help doctor identify patient risk . PURPOSE : Genetic testing study patient family history colorectal cancer identify patient risk develop colorectal cancer .</brief_summary>
	<brief_title>Genetic Study Patients Families With History Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Select patient colon cancer family high-risk colon cancer collect leukocyte DNA , immortalize cell line , plasma , tumor specimen individual control individual . II . Develop patient education , counseling , follow plan individual . III . Compare frequency defective DNA mismatch repair individual familial colon cancer versus colon cancer use antibody hMSH2 hMLH1 protein product . OUTLINE : This multicenter study . Patients , family member , control individual complete extend telephone interview , extend personal interview , epidemiological survey , contribute blood specimen . Blood tumor specimen examine specific pattern immunohistochemical expression hMSH2 HMLH1 determine frequency lack expression two protein product . Patients may contact periodically ( every 3 year ) update information health , health practice , family history . Patients receive result genetic test result influence type duration treatment . PROJECTED ACCRUAL : At least 500-600 family ( approximately 1500 patient ) number match control accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Primary colorectal cancer participate one follow NCCTG protocol : NCCTG784852 : No Treatment Control Versus Levamisole Versus Levamisole Plus 5Fluorouracil NCCTG794604 : No Treatment Control Versus 5FU Portal Vein Infusion NCCTG794751 : Postoperative Radiation Versus Postoperative Radiation Plus Sequential Chemotherapy Methyl CCNU 5FU NCCTG844652 : An Intergroup Study An Evaluation Levamisole Alone Levamisole Plus 5Fluorouracil Surgical Adjuvant Treatment Resectable Adenocarcinoma Colon NCCTG864751 : Phase III Protocol Surgical Adjuvant Therapy Rectal Carcinoma : A Controlled Evaluation ( A ) ProtractedInfusion5Fluorouracil ( 5FU ) Radiation Enhancer ( B ) 5FU Plus MethylCCNU Chemotherapy NCCTG874651 : M/N A Controlled Evaluation Recombinant InterferonGamma ( IFNGM ) 5FU Folinic Acid With Without Levamisole Adjuvant Treatment Resectable Adenocarcinoma Colon NCCTG894651 : A Controlled Phase III Evaluation 5Fluorouracil Levamisole Leucovorin Adjuvant Treatment Resectable Colon Cancer NCCTG914653 : A Phase III Evaluation HighDose Levamisole Plus 5Fluorouracil Leucovorin Surgical Adjuvant Therapy HighRisk Colon Cancer Adequate tissue review OR Families patient meet criterion OR Colon cancer patient population control highrisk family OR Spouse highrisk colon cancer patient PATIENT CHARACTERISTICS : Age : Not specify Performance status : See Disease Characteristics Life expectancy : See Disease Characteristics Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>